Los Angeles-based Cedars-Sinai Health Sciences University co-developed an AI platform that can predict which of two approved chemotherapy regimens for advanced pancreatic cancer is likely to be more effective for a given patient.
The platform analyzes scanned images of standard tumor biopsy slides, according to a March 3 news release from Cedars-Sinai. Researchers evaluated tissue samples from 25,000 pancreatic cancer patients who received one of the two chemotherapy options and examined more than 30,000 tissue features to match characteristics with treatment response.
In the study, published Feb. 11 in Journal of Clinical Oncology, the tool accurately predicted each patient’s response to the therapy they received. Unlike traditional biomarker testing, the approach requires only a digital image of an existing biopsy slide rather than additional blood or tissue samples.
Investigators said the platform could eventually be applied to other solid tumor types and to compare different treatment modalities, including chemotherapy, radiation therapy and surgery.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
